According to a phase II study performed in Japan with elderly patients with advanced NSCLC harboring EGFR mutations (NEJ003), where the toxicities were evaluated beyond 30 days, first-line treatment with gefitinib was concluded to be tolerable [10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.